Envestnet Portfolio Solutions Inc. Reduces Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Envestnet Portfolio Solutions Inc. cut its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 22.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,203 shares of the medical research company’s stock after selling 2,074 shares during the period. Envestnet Portfolio Solutions Inc.’s holdings in Charles River Laboratories International were worth $1,330,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of CRL. Versant Capital Management Inc lifted its position in Charles River Laboratories International by 1,071.4% during the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 150 shares in the last quarter. Pinnacle Bancorp Inc. lifted its position in shares of Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after buying an additional 65 shares in the last quarter. Tortoise Investment Management LLC grew its stake in shares of Charles River Laboratories International by 77.7% during the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock valued at $49,000 after acquiring an additional 115 shares during the period. Wilmington Savings Fund Society FSB purchased a new stake in Charles River Laboratories International in the 3rd quarter worth approximately $59,000. Finally, ORG Wealth Partners LLC bought a new stake in Charles River Laboratories International during the 4th quarter worth approximately $56,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Analyst Ratings Changes

CRL has been the subject of a number of analyst reports. Redburn Atlantic raised shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price objective for the company in a research note on Monday, March 3rd. UBS Group reissued a “neutral” rating and set a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. William Blair lowered Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. The Goldman Sachs Group downgraded Charles River Laboratories International from a “buy” rating to a “neutral” rating and decreased their target price for the company from $190.00 to $170.00 in a research note on Friday. Finally, Citigroup upgraded Charles River Laboratories International from a “sell” rating to a “neutral” rating and upped their price target for the stock from $155.00 to $175.00 in a research note on Tuesday, March 4th. One analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $189.77.

Insider Buying and Selling

In related news, EVP Joseph W. Laplume sold 4,400 shares of the business’s stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the transaction, the executive vice president now owns 20,013 shares in the company, valued at $3,252,112.50. The trade was a 18.02 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Birgit Girshick bought 1,514 shares of Charles River Laboratories International stock in a transaction on Thursday, February 20th. The stock was acquired at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the purchase, the chief operating officer now owns 55,058 shares of the company’s stock, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Trading Up 1.2 %

Shares of NYSE CRL opened at $167.29 on Friday. Charles River Laboratories International, Inc. has a 1-year low of $150.79 and a 1-year high of $273.57. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The business’s 50 day moving average is $166.11 and its two-hundred day moving average is $183.71. The stock has a market capitalization of $8.55 billion, a P/E ratio of 1,115.26, a PEG ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.16. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. Charles River Laboratories International’s quarterly revenue was down 1.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.46 EPS. As a group, research analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).